Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Approves First Drug for The Prevention of Acute Graft Versus Host Disease
The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of ac…
Patient Education Webcasts
Blood Cancers: Managing Side Effects
Research
Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL
SUMMERLIN, Nev., Dec. 14, 2021 - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization o…
Research
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December 11 2021 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 tria…
News
FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse
The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectabl…
Patient Education Webcasts
Non-Hodgkin Lymphoma: Know Your Subtype
Professional Education Webcasts
Blood Cancer 201: Moving Beyond the basics of Disease, Treatment and the Role of the HCP
This accredited CE activity is intended for social workers, nurses, and other healthcare professionals involved in the care of patients with hematolog…
News
LLS Applauds House Passage of Critical Health Reforms
The Leukemia & Lymphoma Society applauds passage of critical patient-friendly reforms by the U.S. House of Representatives. The provisions, components…
News
FDA Approves the First Interferon for Adults With Polycythemia Vera
This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare f…
Research
Kymera Therapeutics Receives IND Clearance for KT-333, a STAT3 Degrader, for the Treatment of Hematologic and Solid Malignancies
WATERTOWN, Mass., Nov. 10, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degr…
Research
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting
Heidelberg, Germany, October 01, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
Professional Education Webcasts
AML Strategies: Decision-Making at Each Point in Care
This series of four modules will provide members of the multidisciplinary cancer care team with the latest information to improve their knowledge and …
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
